Treatment parameters modulating regression of human melanoma xenografts by an antibody-drug conjugate (CR011-vcMMAE) targeting GPNMB

Cancer Chemotherapy and Pharmacology

Volumn 60, Issue 3, 2007, Pages 423-435

  Pollack, Vincent A ^a   Alvarez, Enrique ^a   Tse, Kam Fai ^a   Torgov, Michael Y ^a   Xie, Sam ^a   Shenoy, Suresh G ^a   MacDougall, John R ^a   Arrol, Sharon ^a   Zhong, Haihong ^a   Gerwien, Robert W ^a   Hahne, William F ^a   Senter, Peter D ^b   Jeffers, Michael E ^a   Lichenstein, Henri S ^a   LaRochelle, William J ^a  

^a CURAGEN CORPORATION   (United States)

^b SEATTLE GENETICS INC   (United States)

Author keywords

Antibody drug conjugate (ADC); CR011 vcMMAE; GPNMB; Melanoma; Xenograft

Indexed keywords

ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; CARMUSTINE; CISPLATIN; DOXORUBICIN; FLUOROURACIL; INTERLEUKIN 8; MONOCLONAL ANTIBODY CR O11 PLUS MALEIMIDOCAPROYLVALYLCITRULLINE MONOMETHYLAURISTATIN E; PACLITAXEL; UNCLASSIFIED DRUG; VINBLASTINE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BOLUS INJECTION; CANCER GROWTH; CANCER INHIBITION; CANCER MODEL; CANCER REGRESSION; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INTERMITTENT THERAPY; FEMALE; HUMAN; HUMAN CELL; MALE; MELANOMA; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TARGET CELL DESTRUCTION; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; XENOGRAFT;

ADULT; ANIMALS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNOTOXINS; MALE; MELANOMA; MEMBRANE GLYCOPROTEINS; MICE; MICE, NUDE; MIDDLE AGED; NEOPLASM METASTASIS; TRANSPLANTATION, HETEROLOGOUS;

EID: 34250613133     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0490-z     Document Type: Article

References (47)

1. Afar DE, Bhaskar V, Ibsen E, et al (2004) Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancer. Mol Cancer Ther 3:921-932
2. Aldrich TL, Viaje A, Morris AE (2003) EASE vectors for rapid stable expression of recombinant antibodies. Biotechnol Prog 19:1433-1438
3. Atkins MB, Elder DE, Essner R, et al (2006) Innovations and challenges in melanoma: summary statement from the first Cambridge conference. Clin Cancer Res 12:2291s-2296s
4. Bar-Eli M (1999) Role of interleukin-8 in tumor growth and metastasis of human melanoma. Pathobiology 67:12-18
5. Bennicelli JL, Guerry Dt (1993) Production of multiple cytokines by cultured human melanomas. Exp Dermatol 2:186-190
6. Bhaskar V, Law DA, Ibsen E, et al (2003) E-selectin up-regulation allows for targeted drug delivery in prostate cancer. Cancer Res 63:6387-6394
7. Brennecke S, Deichmann M, Naeher H, Kurzen H (2005) Decline in angiogenic factors, such as interleukin-8, indicates response to chemotherapy of metastatic melanoma. Melanoma Res 15:515-522
8. Cruz-Monserrate Z, Mullaney JT, Harran PG, Pettit GR, Hamel E (2003) Dolastatin 15 binds in the vinca domain of tubulin as demonstrated by Hummel-Dreyer chromatography. Eur J Biochem 270:3822-3828
9. Doronina SO, Mendelsohn BA, Bovee TD, Cerveny CG, Alley SC, Meyer DL, Oflazoglu E, Toki BE, Sanderson RJ, Zabinski RF, Wahl AF, Senter PD (2006) Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem 17:114-124
10. Doronina SO, Toki BE, Torgov MY, et al (2003) Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 21:778-784
11. Dykes DJ, Abbott BJ, Mayo JG, et al (1992) Development of human tumor xenograft models for in vivo evaluation of new antitumor drugs. In: Fiebig HH, Berger DP (eds) Immunodeficient mice in oncology. Contrib Oncol, vol 42. Karger, Basel, pp 1-22
12. Fogh J, Fogh JM, Orfeo T (1977) One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J Natl Cancer Inst 59:221-226
13. Francisco JA, Cerveny CG, Meyer DL, et al (2003) cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 102:1458-1465
14. Geran RI, Greenberg NH, Macdonald MM, Schumacher AM, Abbott BJ (1972) Protocols for screening chemical agents and natural products against animal tumors and other biological systems. Cancer Chemother Rep 3:1-104
15. Gitler MS, Sausville EA, Hollingshead M, Shoemaker R (2004) In vivo models for experimental therapeutics relevant to human cancer. Cancer Res 64:8478-8480
16. Hamblett KJ, Senter PD, Chace DF, et al (2004) Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res 10:7063-7070
17. Huang S, DeGuzman A, Bucana CD, Fidler IJ (2000) Nuclear factor-kappaB activity correlates with growth, angiogenesis, and metastasis of human melanoma cells in nude mice. Clin Cancer Res 6:2573-2581
18. Jeffrey SC, Andreyka JB, Bernhardt SX, Kissler KM, Kline T, Lenox JS, Moser RF, Nguyen MT, Okeley NM, Stone IJ, Zhang X, Senter PD (2006) Development and properties of beta-glucuronide linkers for monoclonal antibody-drug conjugates. Bioconjug Chem 17:831-840
19. Johnson JI, Decker S, Zaharevitz D, et al (2001) Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer 84:1424-1431
20. Jordan MA, Wilson L (2004) Microtubules as a target for anticancer drugs. Nat Rev Cancer 4:253-265
21. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Statistical Assoc 53:457-481
22. Kobayashi M, Natsume T, Tamaoki S, Watanabe J, Asano H, Mikami T, Miyasaka K, Miyazaki K, Gondo M, Sakakibara K, Tsukagoshi S (1997) Antitumor activity of TZT-1027, a novel dolastatin 10 derivative. Jpn J Cancer Res 88:316-327
23. Koch AE, Polverini PJ, Kunkel SL, et al (1992) Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 258:1798-1801
24. Lazar-Molnar E, Hegyesi H, Toth S, Falus A (2000) Autocrine and paracrine regulation by cytokines and growth factors in melanoma. Cytokine 12:547-554
25. Le Borgne R, Planque N, Martin P, Dewitte F, Saule S, Hoflack B (2001) The AP-3-dependent targeting of the melanosomal glycoprotein QNR-71 requires a di-leucine-based sorting signal. J Cell Sci 114:2831-2841
26. Lobo ED, Hansen RJ, Balthasar JP (2004) Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 93:2645-2668
27. Lu C, Kerbel RS (1994) Cytokines, growth factors and the loss of negative growth controls in the progression of human cutaneous malignant melanoma. Curr Opin Oncol 6:212-220
28. Mahmood I, Green MD (2005) Pharmacokinetic and pharmacodynamic considerations in the development of therapeutic proteins. Clin Pharmacokinet 44:331-347
29. Mao W, Luis E, Ross S, et al (2004) EphB2 as a therapeutic antibody drug target for the treatment of colorectal cancer. Cancer Res 64:781-788
30. Mattei S, Colombo MP, Melani C, Silvani A, Parmiani G, Herlyn M (1994) Expression of cytokine/growth factors and their receptors in human melanoma and melanocytes. Int J Cancer 56:853-857
31. McDonagh CF, Turcott E, Westendorf L, et al (2006) Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment. Protein Eng Des Sel 19(7):299-307
32. Miyazaki K, Kobayashi M, Natsume T, Gondo M, Mikami T, Sakakibara K, Tsukagoshi S (1995) Synthesis and antitumor activity of novel dolastatin 10 analogs. Chem Pharm Bull (Tokyo) 43:1706-1718
33. Mohammad RM, Varterasian ML, Almatchy VP, Hannoudi GN, Pettit GR, Al-Katib A (1998) Successful treatment of human chronic lymphocytic leukemia xenografts with combination biological agents auristatin PE and bryostatin 1. Clin Cancer Res 4:1337-1343
34. Natsume T, Watanabe J, Tamaoki S, Fujio N, Miyasaka K, Kobayashi M (2000) Characterization of the interaction of TZT-1027, a potent antitumor agent, with tubulin. Jpn J Cancer Res 91:737-747
35. Owen TA, Smock SL, Prakash S, et al (2003) Identification and characterization of the genes encoding human and mouse osteoactivin. Crit Rev Eukaryot Gene Expr 13:205-220
36. Pettit GR, Srirangam JK, Barkoczy J, et al (1995) Antineoplastic agents 337. Synthesis of dolastatin 10 structural modifications. Anticancer Drug Des 10:529-544
37. Plowman J, Dykes DJ, Hollingshead M, Simpson-Herren L, Alley MC (1997) Human tumor xenograft models in NCI drug development Anticancer drug development guide: preclinical screening, clinical trials, and approval. In: Teicher B (ed) Humana Press, Totowa, pp 102-125
38. Pollack VA, Savage DM, Baker DA, et al (1999) Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther 291:739-748
39. Rodeck U (1993) Growth factor independence and growth regulatory pathways in human melanoma development. Cancer Metastasis Rev 12:219-226
40. Schadendorf D, Moller A, Algermissen B, Worm M, Sticherling M, Czarnetzki BM (1993) IL-8 produced by human malignant melanoma cells in vitro is an essential autocrine growth factor. J Immunol 151:2667-2675
41. Shikano S, Bonkobara M, Zukas PK, Ariizumi K (2001) Molecular cloning of a dendritic cell-associated transmembrane protein, DC-HIL, that promotes RGD-dependent adhesion of endothelial cells through recognition of heparan sulfate proteoglycans. J Biol Chem 276:8125-8134
42. Shimkets RA, Lowe DG, Tai JT, et al (1999) Gene expression analysis by transcript profiling coupled to a gene database query. Nat Biotechnol 17:798-803
43. Strieter RM, Kunkel SL, Elner VM, et al (1992) Interleukin-8. A corneal factor that induces neovascularization. Am J Pathol 141:1279-1284
44. Sun MM, Beam KS, Cerveny CG, Hamblett KJ, Blackmore RS, Torgov MY, Handley FG, Ihle NC, Senter PD, Alley SC (2005) Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides. Bioconjug Chem 16:1282-1290
45. Tse KF, Jeffers M, Pollack VA, et al (2006) CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma. Clin Cancer Res 12:1373-1382
46. Weterman MA, Ajubi N, van Dinter IM, et al (1995) nmb, a novel gene, is expressed in low-metastatic human melanoma cell lines and xenografts. Int J Cancer 60:73-81
47. Wu AM, Senter PD (2005) Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol 23:1137-1146